Ivermectin: Enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations

Journal of Antibiotics

Volumn 70, Issue 5, 2017, Pages 495-505

  Crump, Andy ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; ANTIPARASITIC AGENT;

AFRICAN TRYPANOSOMIASIS; ALLERGIC ASTHMA; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BEDBUG BITE; BURULI ULCER; CHAGAS DISEASE; DENGUE; DISEASE CARRIER; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENCEPHALITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LEISHMANIASIS; MALARIA; MYIASIS; NEUROLOGIC DISEASE; NODDING SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; ROSACEA; SCHISTOSOMIASIS; TRICHINOSIS; TUBERCULOSIS; VECTOR CONTROL; ANIMAL; AWARDS AND PRIZES; DRUG DESIGN; DRUG DEVELOPMENT; GLOBAL HEALTH; HISTORY; ISOLATION AND PURIFICATION; JAPAN; PUBLIC HEALTH;

ANIMALS; ANTIPARASITIC AGENTS; DRUG DESIGN; DRUG DISCOVERY; GLOBAL HEALTH; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IVERMECTIN; JAPAN; NOBEL PRIZE; PUBLIC HEALTH;

EID: 85018611257     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2017.11     Document Type: Review

References (130)

1. Campbell, W. C., Fisher, M. H., Stapley, E. O., Albers-Schönberg, G., & Jacob, T. A. Ivermectin: a potent antiparasitic agent. Science 221, 823-828 (1983
2. Campbell, W. C. Ivermectin: an update. Parasitol. Today 1, 10-16 (1985
3. Campbell, W. C. Ivermectin and Abamectin 325 (Springer-Verlag, New York, 1989
4. Campbell, W. C. Use of Ivermectin in Humans 311-323 (Springer-Verlag, New York, 1989
5. Campbell, W. C. Ivermectin as an antiparasitic agent for use in humans. Ann. Rev. Microbiol. 45, 445-474 (1991
6. Campbell, W. C. in Inventive Mindseds (eds Weber R. J., & Perkins D. N.) 194-214 (Oxford University Press, New York, 1992
7. Omura, S., & Crump, A. The life and times of ivermectin-A success story. Nat. Rev. Microbiol. 2, 984-989 (2004
8. Geary, T. G. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol. 21, 530-532 (2005
9. Omura, S. Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents 31, 91-98 (2008
10. Campbell, W. C. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. Curr. Pharm. Biotechnol. 13, 853-865 (2012
11. Crump, A., & Omura, S. Ivermectin, ?wonder drug? from Japan: the human use perspective. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 87, 13-28 (2011
12. Crump, A., Morel, C. M., & Omura, S. The onchocerciasis chronicle: from the beginning to the end?. Trends Parasitol. 28, 280-288 (2012
13. Omura, S., & Crump, A. Ivermectin: panacea for resource-poor communities?. Trends Parasitol. 30, 445-455 (2014
14. Omura, S. Nobel lecture: a splendid gift from the Earth: the origins and impact of the avermectins. Angew. Chem. Int. Ed. Engl. 55, 10190-10209 (2016
15. Burg, R. W., et al. Avermectins, new family of potent anthelmintic agents: producing organisms and fermentation. Antimicrob. Agents Chemother. 15, 361-367 (1979
16. Miller, T. W., et al. Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties. Antimicrob. Agents Chemother. 15, 368-371 (1979
17. Egerton, J. R., et al. Avermectins, new family of potent anthelmintic agents: efficacy of the B1A component. Antimicrob. Agents Chemother. 15, 372-378 (1979
18. World Health Organization. Onchocerciasis and its control report of a WHO Expert Committee on Onchocerciasis Control (WHO/TRS/852) 104, http://apps.who.int/iris/bitstream/10665/37346/1/WHO-TRS-852.pdf (World Health Organization, Geneva, 1995
19. Zoure, H. G., et al. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected. Parasit. Vectors 7, 325 (2014
20. Remme, J. H. F. The African Programme for Onchocerciasis Control: preparing to launch. Trends Parasitol. 11, 403-406 (1995
21. Coffeng, L. E., et al. African Programme for Onchocerciasis Control 1995-2015: updated health impact estimates based on new disability weights. PLoS Negl. Trop. Dis. 8, e2759 (2014
22. World Health Organization. Progress report on the elimination of human onchocerciasis, 2015-2016. Wkly Epidemiol. Rec. 91, 505-514 (2016
23. Tekle, A. H., et al. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infect. Dis. Poverty 5, 66 (2016
24. Kim, Y. E., et al. Control, elimination and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl. Trop. Dis. 9, e0003664 (2015
25. World Health Organization. Global programme to eliminate lymphatic filariasis: progress report 2015. Wkly Epidemiol. Rec. 91, 441-455 (2016
26. Mectizan Donation Program. Annual Highlights: 2015 8 (Mectizan Donation Programme, Atlanta, Georgia, 2016
27. Krotneva, S. P., et al. African Program for Onchocerciasis Control 1995-2010: impact of annual ivermectin mass treatment on Off-Target infectious diseases. PLoS Negl. Trop. Dis. 9, e0004051 (2015
28. van Wyk, J. A., & Malan, F. S. Resistance of field strains of Haemonchus contortus to ivermectin, closantel, rafoxanide and the benzimidazoles in South Africa. Vet. Record 123, 226-228 (1988
29. Horsberg, T. E. Avermectin use in aquaculture. Curr. Pharm. Biotechnol. 13, 1095-1102 (2012
30. Basanez, M. G., et al. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-Analysis. Lancet Infect. Dis. 8, 310-322 (2008
31. Taylor, M. J., Hoerauf, A., & Bockarie, M. Lymphatic filariasis and onchocerciasis. Lancet 376, 1175-1185 (2010
32. Fink, D. W., & Porras, A. G. in Ivermectin and Abamectin (ed. Campbell W. C.) 113-130 (Springer-Verlag, New York, 1989
33. Baraka, O. Z., et al. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur. J. Clin. Pharmacol. 50, 407-410 (1996
34. González Canga, A., et al. The pharmacokinetics and interactions of ivermectin in humans-A mini-review. AAPS J. 10, 42-46 (2008
35. Brown, D. D. R., Siddiqui, S. Z., Kaji, M. D., & Forrester, S. G. Pharmacological characterization of the Haemonchus contortus GABA-gated chloride channel, Hco-UNC-49: modulation by macrocyclic lactone anthelmintics and a receptor for piperazine. Vet. Parasitol. 185, 201-209 (2012
36. Zheng, Y., et al. Identification of two novel Drosophila melanogaster histamine-gated chloride channel subunits expressed in the eye. J. Biol. Chem. 277, 2000-2005 (2002
37. Schnizler, K., et al A novel chloride channel in Drosophila melanogaster is inhibited by protons. J. Biol. Chem. 280, 16254-16262 (2005
38. Li, B. W., Rush, A. C., & Weil, G. J. High level expression of a glutamate-gated chloride channel gene in reproductive tissues of Brugia malayi may explain the sterilizing effect of ivermectin on filarial worms. Int. J. Parasitol. Drugs Drug Resist. 4, 71-76 (2014
39. Ballesteros, C., et al. The effects of ivermectin on Brugia malayi females in vitro: a transcriptomic approach. PLoS Negl. Trop. Dis. 10, e0004929 (2016
40. Moreno, Y., Nabhan, J. F., Solomon, J., Mackenzie, C. D., & Geary, T. G. Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proc. Natl Acad. Sci. USA 107, 20120-20125 (2010
41. Wolstenholme, A. J., Maclean, M. J., Coates, R., McCoy, C. J., & Reaves, B. J. How do the macrocyclic lactones kill filarial nematode larvae?. Invert. Neurosci. 16, 7 (2016
42. Kwarteng, A., Terkoper Ahuno, S., & Osei Akoto, F. Killing filarial nematode parasites: role of treatment options and host immune response. Infect. Dis. Pov. 5, 86 (2016
43. Higazi, T. B., Geary, T. G., & Mackenzie, C. D. Chemotherapy in the treatment, control, and elimination of human onchocerciasis. Res. Rep. Trop. Med. 5, 77-93 (2014
44. Hewitson, J. P., Grainger, J. R., & Maizels, R. M. helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol. Biochem. Parasitol. 167, 1-11 (2009
45. Maizels, R. M., Hewitson, J. P., & Smith, K. A. Susceptibility and immunity to helminth parasites. Curr. Opin. Immunol. 24, 459-466 (2012
46. MacDonald, A. J., et al. Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity. Infect. Immun. 70, 2796-2804 (2002
47. Ali, M. M., et al. Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis. Acta Trop. 84, 49-53 (2002
48. Brattig, N. W. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect. 6, 113-128 (2004
49. Dzik, J. M. Molecules released by helminth parasites involved in host colonization. Acta Biochim. Pol. 53, 33-64 (2006
50. Kircik, L. H., Del Rosso, J. Q., Layton, A. M., & Schauber, J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J. Drugs Dermatol. 15, 325-332 (2016
51. Shinohara, E. H., Martini, M. Z., de Oliveira Neto, H. G., & Takahashi, A. Oral myiasis treated with ivermectin: case report. Braz. Dent. J. 15, 79-81 (2004
52. Pandey, T. R., Shrestha, G. B., Kharel (Sitaula), R., & Shah, D. N A case of orbital myiasis in recurrent eyelid basal cell carcinoma invasive into the orbit. Case Rep. Ophthalmol. Med. 2904346, 4 http://dx.doi.org/10.1155/2016/2904346 (2016
53. Basyoni, M. M., & El-Sabaa, A. A. Therapeutic potential of myrrh and ivermectin against experimental Trichinella spiralis infection in mice. Korean J. Parasitol. 51, 297-304 (2013
54. Strong, L., & Brown, T. A. Avermectins in insect control and biology: a review. Bull. Entomol. Res. 77, 357-389 (1987
55. Jackson, H. C. Ivermectin as a systemic insecticide. Parasitol. Today 5, 146-156 (1989
56. Tesh, R. B., & Guzman, H. Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Am. J. Trop. Med. Hyg. 43, 229-233 (1990
57. Chaccour, C., Lines, J., & Whitty, C. J. M. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans; the potential of oral insecticides in malaria control. J. Infect. Dis. 202, 113-116 (2010
58. Kobylinski, K. C., et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 116, 119-126 (2010
59. Kobylinski, K. C., Sylla, M., Chapman, P. L., Sarr, M. D., & Foy, B. D. Ivermectin mass drug administration for humans disrupts malaria parasite transmission in Senegalese villages. Am. J. Trop. Med. Hyg. 85, 3-5 (2011
60. Panchal, M., et al. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis. 16, e994 (2014
61. Foy, B. D., Kobylinski, K. C., da Silva, I. M., Rasgon, J. L., & Sylla, M. Endectocides for malaria control. Trends Parasitol. 27, 423-428 (2011
62. Chaccour, C. J., et al. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar. J. 14, 243 (2015
63. Mascari, T. M., Mitchell, M. A., Rowton, E. D., & Foil, L. D. Ivermectin as a rodent feed-Through insecticide for control of immature sand flies (Diptera: Psychodidae). J. Am. Mosq. Control Assoc. 24, 323-326 (2008
64. Kadir, M. A., Aswad, H. S., Al-Samarai, A. M., & Al-Mula, G. A. Comparison between the efficacy of ivermectin and other drugs in treatment of cutaneous leishmaniasis. Iraqi J. Vet. Sci. 23(Suppl II), 175-180 (2009
65. Hanafi, H. A., et al. Effects of ivermectin on blood-feeding Phlebotomus papatasi and the promastigote stage of Leishmania major. Vector Borne Zoonotic Dis. 11, 43-52 (2011
66. Rasheid, K. A., & Morsy, T. A. Efficacy of ivermectin on the infectivity of Leishmania major promastigotes. J. Egypt Soc. Parasitol. 28, 207-212 (1998
67. Opara, W. E. K., & Ameh, I. G. Cutaneous leishmaniasis: a report of its treatment with Mectizan in Sokoto, Nigeria. J. Med. Sci. 5, 186-188 (2005
68. Distelmans, W., D?Haeseleer, F., & Mortelmans, J. Efficacy of systemic administration of ivermectin against tsetse flies. Ann. Soc. Belg. Med. Trop. 83, 119-125 (1983
69. Pooda, S. H., Mouline, K., De Meeûs, T., Bengaly, Z., & Solano, P. Decrease in survival and fecundity of Glossina palpalis gambiensis vanderplank 1949 (Diptera; Glossinidae) fed on cattle treated with single doses of ivermectin. Parasit. Vectors 6, 165 (2013
70. Udensi, U. K., & Fagbenro-Beyioku, A. F. Effect of ivermectin on Trypanosoma brucei brucei in experimentally infected mice. J. Vector Borne Dis. 49, 143-150 (2012
71. Pinto Dias, J. C., et al. Ticks, ivermectin and experimental Chagas disease. Mem. Inst. Oswaldo Cruz 100, 829-832 (2005
72. Fallon, P. G., & Doenhoff, M. J. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 51, 83-88 (1994
73. Ismail, M., et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. 60, 932-935 (1999
74. Mendonça-Silva, D. L., Pessôa, R. F., & Noël, F. Evidence for the presence of glutamatergic receptors in adult Schistosoma mansoni. Biochem. Pharmacol. 64, 1337-1344 (2002
75. Lynagh, T., & Lynch, J. W. Ivermectin binding sites in human and invertebrate Cys-loop receptors. Trends Pharmacol. Sci. 33, 432-441 (2012
76. Taman, A., & Ribeiro, P. Characterization of a truncated metabotropic glutamate receptor in a primitive metazoan, the parasitic flatworm Schistosoma mansoni. PLoS ONE 6, e27119 (2011
77. Taman, A., El-Beshbishi, S., El-Tantawy, N., El-Hawary, A., & Azab, M. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentallyinfected mice. J. Coastal Life Med. 2, 817-823 (2014
78. Nunes Alves, S., & de Melo, A. L. Effects of benzodiazepine and ivermectin on Girardia tigrina (Platyhelminthes: Turbellaria). Biosci. J. Uberlândia 29, 209-215 (2013
79. Matha, V., & Weiser, J. Molluscicidal effect of ivermectin on Biomphalaria glabrata. J. Invertebr. Pathol. 52, 354-355 (1988
80. Sheele, J. M., et al. Ivermectin causes Cimex lectularius (Bedbug) morbidity and mortality. J. Emerg. Med. 45, 433-440 (2013
81. Gonser, L., Gonser, C. E., & Schaller, M. Pathogenesis, clinical picture, and current therapy of rosacea. [In German]. Hautarzt 67, 69-82 (2016
82. Siddiqui, K., Stein Gold, L., & Gill, J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-Analysis. Springerplus 5, 1151 (2016
83. Yan, S., et al. Anti-inflammatory effects of ivermectin in a mouse model of allergic asthma. Inflamm. Res. 60, 589-596 (2011
84. Dowell, S. F., et al. Nodding syndrome. Emerg. Infect. Dis. 19, 1374-1383 (2013
85. Winkler, A. S., et al. MRI findings in people with epilepsy and nodding syndrome in an area endemic for onchocerciasis: an observational study. Afr. Health Sci. 13, 529-540 (2013
86. van Bemmel, K., Derluyn, I., & Stroeken, K. Nodding syndrome or disease?. On the conceptualization of an illness-in-The-making. Ethn. Health 19, 100-118 (2014
87. Sejvar, J. J., et al. Clinical, neurological, and electrophysiological features of nodding syndrome in Kitgum, Uganda: an observational case seriesLancet Neurol. 12, 166-174 (2013
88. Kaiser, C., Pion, S., & Boussinesq, M. Head nodding syndrome and river blindness: a parasitologic perspective. Epilepsia 50, 2325-2326 (2009
89. Vogel, G. Mystery disease haunts region. Science 336, 144-146 (2012
90. Foltz, J. L., et al. An epidemiologic investigation of potential risk factors for nodding syndrome in Kitgum District, Uganda. PLoS ONE 8, e66419 (2013
91. Colebunders, R., et al. Nodding syndrome since 2012: recent progress, challenges and recommendations for future research. Trop. Med. Int. Health 20, 194-200 (2015
92. Franklin, K. M., et al. P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Front. Neurosci. 24, 176 (2014
93. Andries, M., Van Damme, P., Robberecht, W., & Van Den Bosch, L. Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 25, 8-16 (2007
94. Bouzat, C. New insights into the structural bases of activation of Cys-loop receptors. J. Physiol. Paris 106, 23-33 (2012
95. Lynagh, T., & Lynch, J. W. Ivermectin binding sites in human and invertebrate Cys-loop receptors. Trends Pharmacol. Sci. 33, 432-441 (2012
96. Estrada-Mondragon, A., & Lynch, J. W. Functional characterization of ivermectin binding sites in α1β2γ2L GABA(A) receptors. Front. Mol. Neurosci. 8, 55 (2015
97. Mastrangelo, E., et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J. Antimcrob. Chemother. 67, 1884-1894 (2012
98. Tay, M. Y., et al. Nuclear localization of dengue virus (DENV) 1-4 nonstructural protein 5: protection against all 4 DENV serotypes by the inhibitor ivermectin. Antiviral Res. 99, 301-306 (2013
99. Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D., & Jans, D. A. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue viruses. Biochem. J. 443(Pt 3), 851-856 (2012
100. Kosyna, F. K., Nage, M., Kluxen, L., Kraushaar, K., & Depping, R. The importin α/β-specific inhibitor ivermectin affects HIF-dependent hypoxia response pathways. Biol. Chem. 396, 1357-1367 (2015
101. Pettengil, M. A., Lam, V. W., Ollawa, I., Marques-da-Silva, C., & Ojcius, D. M. Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells. PLoS ONE 7, e48456 (2012
102. Lim, L. E., Vilchèze, C., Ng, C., Jacobs, W. R. Jr, Ramón-García, S., & Thompson, C. J. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrugresistant clinical strains. Antimicrob. Agents Chemother. 57, 1040-1046 (2013
103. Ameen, S. M., & Drancourt, M. Ivermectin lacks antituberculous activity. J. Antimicrob. Chemother. 68, 1936-1937 (2013
104. Ramón-García, S., et al. Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent. J. Antimicrob. Chemother. 69, 1723-1724 (2014
105. Omansen, T. F., et al. In-vitro activity of avermectins against Mycobacterium ulcerans. PLoS Negl. Trop. Dis. 9, e0003549 (2015
106. Scherr, N., Pluschke, G., Thompson, C. J., & Ramón-García, S. Selamectin is the avermectin with the best potential for Buruli Ulcer treatment. PLoS Negl. Trop. Dis. 9, e0003996 (2015
107. Drinyaev, V. A., et al. Antitumor effect of avermectins. Eur. J. Pharmacol. 501, 19-23 (2004
108. Driniaev, V. A., et al. Modification of antitumor effect of vincristine by natural avermectins. [In Russian]. Antibiot. Khimioter. 49, 3-5 (2004
109. Lee, H., Kang, S., & Kim, W. Drug repositioning for cancer therapy based on large-scale drug-induced transcriptional signatures. PLoS ONE 11, e0150460 (2016
110. Hashimoto, H., Sudo, T., Maruta, H., & Nishimura, R. The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423. Drug Discov. Ther. 4, 1-4 (2010
111. Dou, Q., et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res. 76, 4457-4469 (2016
112. Kwon, Y. J., et al. Selective inhibition of SIN3 co-repressor with avermectins as a novel therapeutic strategy in triple-negative breast cancer. Mol. Cancer. Ther. 14, 1824-1836 (2015
113. Sharmeen, S., et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood 116, 3593-3603 (2010
114. Shen, M., et al. Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS ONE 8, e75252 (2013
115. Furusawa, S., et al. Potentiation of doxorubicin-induced apoptosis of resistant mouse leukaemia cells by ivermectin. Pharm. Pharmacol. Commun. 6, 129-134 (2000
116. Draganov, D., et al. Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-Apoptotic and inflammatory form of cancer cell death. Sci. Rep. 10, 16222 (2015
117. Melotti, A., et al. The river blindness drug ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol. Med. 6, 1263-1278 (2014
118. Ashraf, S., & Prichard, R. Ivermectin exhibits potent anti-mitotic activity. Vet. Parasitol. 226, 1-4 (2016
119. Tibbit, M. W., Dahlman, J. E., & Langer, R. Emerging frontiers in drug delivery. J. Am. Chem. Soc. 138, 704-717 (2016
120. González, P., González, F. A., & Ueno, K. Ivermectin in human medicine, an overview of the current status of its clinical applications. Curr. Pharm. Biotechnol. 13, 1103-1109 (2012
121. N.d. Drugs for parasitic infections. Med. Lett. Drugs Ther. 143, e1-31 (2013
122. Guzzo, C. A., et al. Safety, tolerability and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol. 42, 1122-1133 (2002
123. Gamboa, G. V., et al. Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications. Parasitol. Res. 115, 1945-1953 (2016
124. Clark, S. L., Crowley, A. J., Schmidt, P. G., Donoghue, A. R., & Piché, C. A. Long-Term delivery of ivermectin by use of poly(D, L-lactic-co-glycolic)acid microparticles in dogs. Am. J. Vet. Res. 65, 752-757 (2004
125. Miller, A. J., Oehler, D. D., & Pound, M. J. Delivery of ivermectin by injectable microspheres. J. Econ. Entomol. 91, 655-659 (1998
126. Liu, X., Sun, Q., Wang, H., Zhang, L., & Wang, J.-Y. Microspheres of corn protein, zein, for an ivermectin drug delivery system. Biomaterials 26, 109-115 (2005
127. Ding, D., Sheng, X.-L., Liang, K.-X., Xu, Q., & Liu, W. Study on ivermectin nanoemulsion for transdermal drug delivery. China Animal Husbandry Vet. Med. J. 42, 401-407 (2015
128. Chaccour, C., et al. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar. J. 14, 102 (2015
129. Miyajima, A., et al. Experimental study of pharmacokinetics of external, whole-body bathing application of ivermectin. J. Dermatol. 42, 87-89 (2015
130. Yardley, M. M., Huynh, N., Rodgers, K. E., Alkana, R. L., & Davies, D. L. Oral delivery of ivermectin using a fast dissolving oral film: implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol 49, 553-559 (2015